King Pharmaceuticals Inc.

Brian A. Markison currently serves as President, Chief Executive Officer and Chairman of the Board of Directors of King Pharmaceuticals, Inc. Prior to joining King Pharmaceuticals, Mr. Markison was the President of Oncology, Virology and Oncology Therapeutics Network Business at Bristol-Meyers Squibb. During his 22-year career at Bristol-Meyers Squibb, he distinguished himself in the areas of sales, marketing, international and domestic general management positions.

Mr. Squicciarino has served as the Chief Financial Officer of King Pharmaceuticals, Inc. since June 2005. Prior to joining King Pharmaceuticals, he served as Chief Financial Officer—North America for Revlon, Inc. from March 2005 until June 2009 and as Chief Financial Officer—International for Revlon International, Inc. from February 2003 until March 2005. He held the position of Group Controller Pharmaceuticals—Europe, Middle East, Africa with Johnson & Johnson from October 2001 until October 2002.

Marsha Stanton is a registered nurse with a bachelor's degree in Health Services Administration and Education, a Master of Science in Health & Human Services, and a PhD in Health Services Administration and Education. She currently serves as the Director of Advocacy and External Affairs at King Pharmaceuticals. Her career has spanned clinical practice, program development, health professionals education, and advocacy development. She is nationally known for her work in the area of pain management, and has published and presented in this field. She has served in leadership roles with the American Society of Pain Management Nurses, Utah Pain Management Nurses, American Academy of Pain Management, and Pain Management Education Consultants. Prior to assuming her new position, she served as the Director of Medical Education at Purdue Pharma, L.P. and Director of Scientific Communication at Alpharma Pharmaceuticals. In these positions, she was responsible for professional education of nurses, nurse practitioners, physician assistants, physicians, pharmacists, and others at national, regional and international levels. In these roles, she served on the corporate advisory council for six professional associations. In 2006, she received the Distinguished Service Award from the American Society of Pain Management Nurses.

Dr. Polk has disclosed that she is a consultant for King Pharmaceuticals. She is also on the speakers' bureau for King Pharmaceuticals, Astellas Pharma, and Amgen.

Dr. Gonzalez has disclosed that he is a consultant for King Pharmaceuticals. He is also on the speakers' bureaus for Astellas Pharma, Amgen, and King Pharmaceuticals.

Dr. Raymond Gibbons was born in New York City and grew up in northern New Jersey. He obtained a BSE in Aerospace and Mechanical Sciences from Princeton University, where he was valedictorian of his class. He completed a MSc in Mathematics at New College, Oxford University, where he studied on a Rhodes scholarship. After a year of graduate work in biomedical engineering at Johns Hopkins University, he completed his MD at Harvard Medical School, where he was a member of the Harvard-Massachusetts Institute of Technology Program in Health Sciences and Technology. He then completed a residency in internal medicine at Massachusetts General Hospital and a cardiology fellowship at Duke University Medical Center. In 1981, he joined the cardiology staff at the Mayo Clinic. Since that time, he has been Co-director of the Nuclear Cardiology Laboratory. In 1997, he was named the Arthur M. and Gladys D. Gray Professor of Medicine at Mayo Medical School. He has received numerous Mayo teaching awards in Internal Medicine and Cardiovascular Diseases. He is past Chair of the ACC-AHA Task Force on Practice Guidelines, past Chair of the ACC-AHA Writing Committee for Guidelines for Exercise Testing, Chair of the ACC Guidelines Applied in Practice Committee, and Chair of the Committee on Scientific Sessions Program of the AHA. He also serves as a member of the Board of Trustees of the American College of Cardiology and the Science Advisory and Coordinating Committee (the highest scientific policy group) of the AHA. Dr. Gibbons receives grant support from Medco Research (a division of King Pharmaceuticals), Wyeth-Ayerst, Medtronic, Radiant Medical, Alsius Corporation, TherOx, and Innercool Therapies. He is a consultant to CV Therapeutics, DOV Pharmaceuticals, King Pharmaceuticals, Medicure, Boehringer Ingelheim, and Hawaii Biotech. King Pharmaceuticals manufactures an angiotensin-converting enzyme (ACE) inhibitor. Because of this conflict of interest, he did not participate in the decision by the ACC/AHA Writing Committee for Guidelines for the Management of Patients with Chronic Stable Angina to recommend the use of ACE inhibitors.

R. Charles Moyer is the Dean of the College of Business and Public Administration at the University of Louisville. Prior to joining the faculty at the University of Louisville, Dean Moyer was the Dean of the Babcock Graduate School of Management at Wake Forest University from 1996 until 2003. He also held the GMAC Insurance Chair of Finance. During his tenure as Dean, the Babcock School was named among the top business schools in the world in every major ranking of MBA programs. Prior to joining the faculty at Wake Forest in 1988, he was Finance Department Chairman at Texas Tech University. He has also taught at the University of Houston, Lehigh University, and the University of New Mexico. Dean Moyer is a member of the Board of Directors of King Pharmaceuticals, Inc. and Amarr Garage Doors, Inc.

Mr. Deavenport has served as a Director since October 2007. He is the retired Chairman and Chief Executive Officer of Eastman Chemical Company, and served in those positions from 1994 to 2002. Mr. Deavenport served as a director of Acuity Brands from June 2002 until October 2007. Mr. Deavenport serves as Lead Director, is Chairman of our Compensation Committee and is a member of our Nominating and Corporate Governance Committee. He is a director of King Pharmaceuticals, Inc. and Regions Financial Corporation.